TY - JOUR T1 - ApharSeq: An Extraction-free Early-Pooling Protocol for Massively Multiplexed SARS-CoV-2 Detection JF - medRxiv DO - 10.1101/2020.08.08.20170746 SP - 2020.08.08.20170746 AU - Alon Chappleboim AU - Daphna Joseph-Strauss AU - Ayelet Rahat AU - Israa Sharkia AU - Miriam Adam AU - Daniel Kitsberg AU - Gavriel Fialkoff AU - Matan Lotem AU - Omer Gershon AU - Anna-Kristina Schmidtner AU - Esther Oiknine-Djian AU - Agnes Klochendler AU - Ronen Sadeh AU - Yuval Dor AU - Dana Wolf AU - Naomi Habib AU - Nir Friedman Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/26/2020.08.08.20170746.abstract N2 - The global SARS-CoV-2 pandemic created a dire need for viral detection tests worldwide. Most current tests for SARS-CoV-2 are based on RNA extraction followed by quantitative reverse-transcription PCR assays. While automation and improved logistics increased the capacity of these tests, they cannot exceed the lower bound dictated by one extraction and one RT-PCR reaction per sample. Multiplexed next generation sequencing (NGS) assays provide a dramatic increase in throughput, and hold the promise of richer information including viral strains, host immune response, and multiple pathogens.Here, we establish a significant improvement of existing RNA-seq detection protocols. Our workflow, ApharSeq, includes a fast and cheap RNA capture step, that is coupled to barcoding of individual samples, followed by sample-pooling prior to the reverse transcription, PCR and massively parallel sequencing. Thus, only one non-enzymatic step is performed before pooling hundreds of barcoded samples for subsequent steps and further analysis. We characterize the quantitative aspects of the assay by applying ApharSeq to more than 500 clinical samples in a robotic workflow. The assay results are linear, and the empirical limit of detection is found to be Ct 33 (roughly 1000 copies/ml). A single ApharSeq test currently costs under 1.2$, and we estimate costs can further go down 3-10 fold. Similarly, we estimate a labor reduction of 10-100 fold, automated liquid handling of 5-10 fold, and reagent requirement reduction of 20-1000 fold compared to existing testing methods.Competing Interest Statementsome of the authors are inventors on a patent application with the aim of making this technology freely, widely, and rapidly available for research and clinical testing.Funding StatementThis work was supported in part by the Rothschild Foundation. AC is an Azrieli scholar and would like to thank the Azrieli Foundation for their supportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HADASSAH MEDICAL ORGANIZATION Institutional Review Board (IRB) Membership vhelsinki{at}hadassah.org.ilAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code will be made available upon request. ER -